Business
Successful RSV Challenge Study in Older Adults
Successful RSV Challenge Study in Older Adults.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 9575H hVIVO plc 06 August 2019 \n\nRNS REACH\n \n \nhVIVO plc\n(\"hVIVO\" or the \"Company\")\n \nhVIVO successfully completes RSV challenge study in Older Adults \n \n- Represents a new model available to customers as part of hVIVO's clinical trial services offering -\n \n- Respiratory syncytial virus (RSV) human challenge study conducted by hVIVO in adults aged 60-75 delivers positive results\n- Study demonstrated that an RSV challenge study can be performed safely in this age group\n- Broadens hVIVO's commercial offering in RSV beyond its already established RSV model in the younger population\n- Utilisation of the Older Adult model targets population associated with significant unmet need in RSV\n \nLondon, UK - 6 August 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, announces the successful completion of an RSV human challenge study conducted in older adults, aged 60-75 years. The study was conducted at hVIVO's specialist clinical facility in London.\n \nThe study demonstrated that an RSV challenge model can be conducted safely in a population of 60-75 years of age.\n \nThe study, which extends hVIVO's commercial provision beyond the established RSV human challenge model in 18-60 year olds, comprised volunteers who were residential in hVIVO's state of the art human challenge clinical unit for a period of approximately 2 weeks after being inoculated with hVIVO's GMP-manufactured RSV Memphis 37 Challenge virus strain. Each volunteer was closely monitored 24 hours a day with data concerning safety, infection rates, virology and symptoms collected before being safely discharged and followed up for 28 days post discharge.\n \nThe hVIVO RSV Older Adult challenge model in 60-75 year olds, was specifically designed to provide the pharmaceutical industry with an early clinical development proof of concept platform to safely evaluate novel treatments/vaccines in one of the populations with the greatest unmet medical need. \n&n...